Analysts predict that China Biologic Products, Inc. (NASDAQ:CBPO) will report $1.02 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for China Biologic Products’ earnings. China Biologic Products reported earnings of $0.95 per share in the same quarter last year, which indicates a positive year over year growth rate of 7.4%. The company is scheduled to announce its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that China Biologic Products will report full-year earnings of $5.02 per share for the current fiscal year, with EPS estimates ranging from $5.01 to $5.02. For the next fiscal year, analysts expect that the company will post earnings of $5.64 per share, with EPS estimates ranging from $5.49 to $5.78. Zacks’ EPS calculations are an average based on a survey of research analysts that cover China Biologic Products.

A number of research analysts recently commented on CBPO shares. BidaskClub cut China Biologic Products from a “hold” rating to a “sell” rating in a research report on Sunday, July 16th. Jefferies Group LLC restated a “buy” rating on shares of China Biologic Products in a research report on Friday, August 4th. Finally, Zacks Investment Research cut China Biologic Products from a “hold” rating to a “sell” rating in a research report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. China Biologic Products has an average rating of “Hold” and a consensus price target of $137.50.

China Biologic Products (NASDAQ CBPO) traded up $7.40 on Monday, hitting $84.96. The stock had a trading volume of 371,998 shares, compared to its average volume of 592,211. China Biologic Products has a 12 month low of $72.21 and a 12 month high of $125.99. The firm has a market capitalization of $2,141.38, a P/E ratio of 17.27, a P/E/G ratio of 1.26 and a beta of 1.71.

A number of institutional investors have recently added to or reduced their stakes in the business. Jennison Associates LLC grew its position in China Biologic Products by 0.8% in the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock valued at $653,000 after acquiring an additional 44 shares during the last quarter. OxFORD Asset Management LLP grew its position in China Biologic Products by 1.6% in the second quarter. OxFORD Asset Management LLP now owns 14,748 shares of the biopharmaceutical company’s stock valued at $1,668,000 after acquiring an additional 236 shares during the last quarter. California Public Employees Retirement System grew its position in China Biologic Products by 3.1% in the second quarter. California Public Employees Retirement System now owns 29,500 shares of the biopharmaceutical company’s stock valued at $3,336,000 after acquiring an additional 900 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in China Biologic Products in the first quarter valued at about $156,000. Finally, Geode Capital Management LLC grew its position in China Biologic Products by 15.4% in the first quarter. Geode Capital Management LLC now owns 14,309 shares of the biopharmaceutical company’s stock valued at $1,432,000 after acquiring an additional 1,906 shares during the last quarter. Hedge funds and other institutional investors own 71.85% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/06/zacks-analysts-expect-china-biologic-products-inc-cbpo-to-announce-1-02-earnings-per-share.html.

China Biologic Products Company Profile

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for China Biologic Products (NASDAQ:CBPO)

Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.